This single-arm trial (n=15) aims to assess the safety, tolerability, and feasibility of using psilocybin (25mg) in combination with psychotherapy for methamphetamine use disorder.
Pilot single-group Phase I study delivering three 90-minute preparatory psychotherapy sessions, one supervised 25 mg oral psilocybin dosing session (~8 hours), and two 60-minute integration sessions over a 4-week intervention period for participants with methamphetamine use disorder.
Outcomes include safety and tolerability (AEs per CTCAE v5.0), methamphetamine use by timeline followback and urine drug screening at baseline, dosing day, and days 1, 7, and 28 post-dose; adherence supported by session checklists and filming of dosing day.
Single-group psilocybin-assisted psychotherapy intervention for methamphetamine use disorder: preparatory sessions, a single supervised 25 mg psilocybin dosing session, and integration sessions.
25 mg oral capsule administered 1–2 days after last preparatory session; supervised dosing day (~8 hours).
Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.